395 related articles for article (PubMed ID: 26306819)
21. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.
Einarson TR; Bereza BG; Garcia Llinares I; González Martín Moro B; Tedouri F; Van Impe K
J Med Econ; 2017 Oct; 20(10):1039-1047. PubMed ID: 28678566
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
[TBL] [Abstract][Full Text] [Related]
23. Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study.
Savitz AJ; Xu H; Gopal S; Nuamah I; Hough D; Mathews M
Int Clin Psychopharmacol; 2017 Nov; 32(6):329-336. PubMed ID: 28806194
[TBL] [Abstract][Full Text] [Related]
24. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort.
Martínez-Andrés JA; García-Carmona JA
Int Clin Psychopharmacol; 2020 May; 35(3):163-169. PubMed ID: 31851035
[TBL] [Abstract][Full Text] [Related]
25. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
[TBL] [Abstract][Full Text] [Related]
26. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic.
Lai JK; Margolese HC
Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989
[No Abstract] [Full Text] [Related]
27. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
[No Abstract] [Full Text] [Related]
28. Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.
Samtani MN; Nandy P; Ravenstijn P; Remmerie B; Vermeulen A; Russu A; D'hoore P; Baum EZ; Savitz A; Gopal S; Hough D
Br J Clin Pharmacol; 2016 Nov; 82(5):1364-1370. PubMed ID: 27333588
[TBL] [Abstract][Full Text] [Related]
29. An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate.
Kern Sliwa J; Savitz A; Nuamah I; Mathews M; Gopal S; Elefant E; Najarian D; Alphs L
Perspect Psychiatr Care; 2018 Oct; 54(4):530-538. PubMed ID: 29446084
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.
Russu A; Savitz A; Mathews M; Gopal S; Feng Y; Samtani MN
J Clin Psychopharmacol; 2019; 39(6):567-574. PubMed ID: 31688450
[TBL] [Abstract][Full Text] [Related]
31. Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections.
Debaveye S; De Smedt D; Heirman B; Kavanagh S; Dewulf J
BMC Health Serv Res; 2019 Jun; 19(1):393. PubMed ID: 31217000
[TBL] [Abstract][Full Text] [Related]
32. A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly.
Geerts H; Spiros A; Roberts P; Alphs L
Schizophr Res; 2018 Jul; 197():261-268. PubMed ID: 29395607
[TBL] [Abstract][Full Text] [Related]
33. Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
Turkoz I; Daskiran M; Siddiqui U; Knight RK; Johnston KL; Correll CU
Int J Neuropsychopharmacol; 2024 Feb; 27(2):. PubMed ID: 38300235
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults.
Cirnigliaro G; Battini V; Castiglioni M; Renne M; Mosini G; Cheli S; Carnovale C; Dell'Osso B
Expert Rev Neurother; 2024 Apr; 24(4):325-332. PubMed ID: 38445396
[TBL] [Abstract][Full Text] [Related]
36. Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting.
Cirnigliaro G; Battini V; Cafaro R; Mosini G; Vanzetto S; Prodi T; Macellaro M; Leuzzi R; Conti D; Carnovale C; Dell'Osso B
Expert Rev Neurother; 2023; 23(11):1031-1039. PubMed ID: 37750003
[TBL] [Abstract][Full Text] [Related]
37. Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study.
Wallman P; Clark I; Taylor D
J Psychiatr Res; 2022 Apr; 148():131-136. PubMed ID: 35123325
[TBL] [Abstract][Full Text] [Related]
38. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate.
Mathews M; Nuamah I; Savitz AJ; Hough DW; Najarian D; Kim E; Gopal S
Neuropsychiatr Dis Treat; 2018; 14():2807-2816. PubMed ID: 30498351
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of once-monthly paliperidone palmitate long-acting injection in an elderly patient with schizophrenia.
Rama Raj P; Lewis M; Macfarlane S
BMJ Case Rep; 2015 Aug; 2015():. PubMed ID: 26311017
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
